This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
IRVINE, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Shelley Thunen, Chief Financial Officer, is scheduled to present at the Canaccord Genuity 33rd Annual Growth Conference in Boston, MA.
Canaccord Genuity 33rd Annual Growth Conference
Thursday, August 15, 2013
6:30 a.m. PT / 9:30 a.m. ET
An audio webcast of the Company's presentation will be available by visiting the investor relations section of Endologix's website at
www.endologix.com . A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at
CONTACT: COMPANY CONTACT:
John McDermott, CEO
Shelley Thunen, CFO
The Ruth Group